126. Clin Cancer Res. 2018 Aug 1;24(15):3480-3482. doi: 10.1158/1078-0432.CCR-18-0759.Epub 2018 Apr 19.Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor DegradersArrive.Jordan VC(1).Author information: (1)Department of Breast Medical Oncology, The University of Texas MD AndersonCancer Center, Houston, Texas. vcjordan@mdanderson.org.Predictive tests, to refine the estrogen receptor assay, for the adjuvanttreatment of breast cancer with tamoxifen and oral selective estrogen receptordegraders (SERD) are required. A splice variant of the corepressor NCOR2,BQ2313636.1 predicts tamoxifen resistance to adjuvant tamoxifen and AZ9496, thefirst oral SERD, completes phase I studies. Clin Cancer Res; 24(15); 3480-2.©2018 AACRSee related articles by Gong et al., p. 3681 and Hamilton et al., p.3510.©2018 American Association for Cancer Research.DOI: 10.1158/1078-0432.CCR-18-0759 PMCID: PMC6082682 [Available on 2019-02-01]PMID: 29674510 